The blockbuster success of GLP-1 weight loss drugs has caused major ripple effects across healthcare and pharma, representing a significant growth engine for drugmakers but a cost challenge for payers. GLP-1s are also potentially disrupting a healthcare system built around treating obesity-related complications, forcing providers, insurers and investors to rethink where future revenue and growth will come from, according to a new report from Wells Fargo. As the use of GLP-1 drugs for weight loss continues to grow, there will be downstream impacts to cardiology service lines and chronic disease management as well, the report notes.
Read the full article: GLP-1s Are Forcing a Strategic Reset Across Healthcare: Wells Fargo Report //
Source: https://www.fiercehealthcare.com/providers/glp-1s-forcing-strategic-reset-across-healthcare-well-fargo-report